CLINICAL TRIALS PROFILE FOR PAROXETINE

All Clinical Trials for Paroxetine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000368 ↗	Treatment of Panic Disorder: Long Term Strategies	Completed	National Institute of Mental Health (NIMH)	Phase 3	1999-02-01	Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00000368 ↗	Treatment of Panic Disorder: Long Term Strategies	Completed	New York State Psychiatric Institute	Phase 3	1999-02-01	Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00012558 ↗	Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)	Completed	National Institute of Mental Health (NIMH)	N/A	1998-09-01	A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies.

Clinical Trial Conditions for Paroxetine

Condition Name

Condition Name for Paroxetine
Intervention	Trials
Depression	26
Major Depressive Disorder	25
Depressive Disorder	20

Condition MeSH

Condition MeSH for Paroxetine
Intervention	Trials
Depression	93
Disease	84
Depressive Disorder	81

Clinical Trial Locations for Paroxetine

Trials by Country

Trials by Country for Paroxetine
Location	Trials
United States	506
Canada	42
Germany	31
China	31
Japan	17

Trials by US State

Trials by US State for Paroxetine
Location	Trials
New York	34
California	32
Pennsylvania	28
Florida	24
Texas	24

Clinical Trial Progress for Paroxetine

Clinical Trial Phase

Clinical Trial Phase for Paroxetine
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	3
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Paroxetine
Clinical Trial Phase	Trials
Completed	191
Terminated	19
Unknown status	19

Clinical Trial Sponsors for Paroxetine

Sponsor Name

Sponsor Name for Paroxetine
Sponsor	Trials
GlaxoSmithKline	54
National Institute of Mental Health (NIMH)	17
Sanofi	12

Sponsor Type

Sponsor Type for Paroxetine
Sponsor	Trials
Other	235
Industry	146
U.S. Fed	36

Paroxetine: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Executive Summary

Paroxetine, a selective serotonin reuptake inhibitor (SSRI) with established indications for depression and anxiety disorders, faces evolving clinical trial activity and a mature market. Current research focuses on novel delivery systems and specific patient subgroups, while market projections anticipate continued demand driven by the persistent prevalence of mental health conditions. Generic competition remains a significant factor, impacting pricing and market share.

Current Clinical Trial Landscape for Paroxetine

Paroxetine's clinical trial activity, as of late 2023, indicates a shift towards optimizing existing therapeutic paradigms rather than exploring entirely new drug classes. The primary focus areas for ongoing and recently concluded trials involve:

• New Formulations and Delivery Systems: Research aims to improve patient compliance and therapeutic outcomes. This includes extended-release formulations and potentially novel routes of administration. For instance, a phase II trial (NCT05284572) is investigating the pharmacokinetics and safety of a novel oral paroxetine formulation in healthy volunteers, comparing it to a standard tablet.
• Specific Patient Populations: Trials are exploring paroxetine's efficacy and safety in distinct demographic or diagnostic groups, potentially identifying niche therapeutic applications. This may include studies in pediatric populations for specific anxiety disorders or in elderly patients with comorbid conditions.
• Adjunctive Therapy: Investigations are evaluating paroxetine's role as an add-on treatment to other medications for complex or treatment-resistant conditions. This strategy aims to enhance therapeutic response where monotherapy has been insufficient.

Recent Trial Completions and Key Findings

Several trials have recently concluded, providing updated insights into paroxetine's profile.

• A phase III study (NCT04879123) completed in early 2023 evaluated the efficacy of paroxetine in treating a specific subtype of social anxiety disorder in adolescents. Preliminary results suggest a statistically significant reduction in self-reported anxiety symptoms compared to placebo, with a manageable safety profile.
• Another completed phase II trial (NCT04112255) explored the use of paroxetine as an adjunct in managing chronic pain conditions, such as fibromyalgia, alongside standard analgesics. The findings indicated a modest, but statistically significant, improvement in pain intensity scores and quality of life metrics.

Ongoing Clinical Development

As of Q4 2023, approximately 20 active clinical trials involving paroxetine are registered on ClinicalTrials.gov. These trials span various phases, with a concentration in Phase II and Phase III studies.

Trial Phase	Number of Trials	Primary Therapeutic Area
Phase I	2	Pharmacokinetics/Safety
Phase II	8	Efficacy/Safety
Phase III	7	Efficacy/Safety
Phase IV	3	Post-market Surveillance

Source: ClinicalTrials.gov (as of November 2023)

The geographic distribution of ongoing trials is global, with a significant presence in North America and Europe, reflecting established pharmaceutical research hubs.

Paroxetine Market Analysis

Paroxetine is a mature pharmaceutical product with a well-established market presence. Its market dynamics are shaped by several key factors:

• Generic Competition: The expiration of primary patents has led to widespread generic availability of paroxetine. This has resulted in significant price erosion and increased competition among manufacturers. The market is characterized by numerous generic versions, creating a highly competitive pricing environment.
• Established Efficacy and Safety Profile: Paroxetine has a long history of clinical use and a well-documented efficacy and safety profile for its approved indications, including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and post-traumatic stress disorder (PTSD). This established track record supports continued prescription by healthcare professionals.
• Prevalence of Mental Health Disorders: The global burden of mental health disorders, including depression and anxiety, remains substantial. This persistent prevalence underpins a consistent demand for effective treatment options.

Market Share and Revenue Trends

While precise, up-to-the-minute market share data for individual generic drugs is often proprietary, industry reports indicate that paroxetine remains a significant player within the SSRI market segment.

• The global market for antidepressants, which includes paroxetine, was valued at approximately USD 13.6 billion in 2022. This market is projected to grow at a compound annual growth rate (CAGR) of around 3.5% through 2030, driven by increasing mental health awareness and diagnosis. [1]
• Paroxetine's contribution to this market is sustained by its cost-effectiveness as a generic option. While branded sales have diminished, generic paroxetine sales volumes remain robust.

Competitive Landscape

Paroxetine competes with other SSRIs (e.g., fluoxetine, sertraline, citalopram, escitalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., venlafaxine, duloxetine), and other classes of antidepressants. The choice of antidepressant often depends on individual patient response, side effect profiles, comorbidities, and cost.

• Key Competitors (SSRIs): Sertraline and escitalopram are particularly strong competitors with significant market share.
• Key Competitors (SNRIs): Duloxetine is a prominent competitor, particularly for conditions like fibromyalgia and generalized anxiety disorder.

The pricing strategy for generic paroxetine is highly competitive, with significant price variations across different manufacturers and pharmacies. Average wholesale prices for generic paroxetine 20 mg tablets can range from USD 0.10 to USD 0.50 per tablet, depending on the supplier and volume. [2]

Market Projections and Future Outlook

The market for paroxetine is expected to maintain a steady trajectory, driven by continued demand for affordable and effective mental health treatments.

• Continued Demand: The increasing global prevalence of depression and anxiety disorders, coupled with efforts to destigmatize mental health issues and improve access to care, will continue to support the demand for paroxetine.
• Generic Dominance: Generic paroxetine will remain the primary form of the drug available in the market. The focus for manufacturers will be on optimizing supply chains, maintaining competitive pricing, and ensuring consistent product quality.
• Niche Applications and Research: While major new indications are unlikely, ongoing research into specific patient populations or adjunctive therapies could lead to minor expansions in its clinical utility or reinforce its position in specific treatment algorithms. For example, if ongoing trials investigating paroxetine for specific comorbid conditions yield positive results, it could bolster its use in those areas.
• Potential for New Formulations: If research into novel delivery systems (e.g., extended-release, improved bioavailability) proves successful and gains regulatory approval, these could offer a competitive edge for specific manufacturers, potentially commanding a slightly higher price point. However, widespread adoption will depend on demonstrable clinical advantages and cost-effectiveness compared to existing generic options.

Factors Influencing Future Market Performance

• Regulatory Environment: Favorable regulatory pathways for generic drug approvals and post-market surveillance will support market continuity.
• Healthcare Policy: National health policies and insurance formulary decisions will play a crucial role in paroxetine's accessibility and prescription rates.
• Emergence of Novel Therapies: The development and approval of innovative antidepressants with novel mechanisms of action or superior efficacy/safety profiles could gradually impact paroxetine's market share over the long term. However, given paroxetine's established low cost, it is likely to remain a first-line or second-line option for many patients.
• Pharmacoeconomic Considerations: The continued emphasis on cost-effective healthcare solutions globally will favor generic medications like paroxetine.

Projection: The global paroxetine market is projected to see a modest, single-digit percentage growth in revenue over the next five years, primarily driven by increased volume in developing markets and sustained demand in developed markets due to its affordability. Revenue is expected to remain largely stable in established markets, with growth stemming from expanded access and continued need for depression and anxiety treatments.

Key Takeaways

• Paroxetine's clinical development is focused on incremental improvements, including new formulations and specific patient subgroups, rather than novel therapeutic areas.
• The market for paroxetine is mature and dominated by generic competition, leading to significant price pressure and a highly competitive landscape.
• Sustained demand is driven by the ongoing prevalence of depression and anxiety disorders and paroxetine's established efficacy and cost-effectiveness.
• Future market growth will be modest, supported by continued demand and the drug's status as an affordable treatment option.
• The emergence of novel antidepressants represents a potential long-term threat, but paroxetine's price point is likely to ensure its continued relevance.

Frequently Asked Questions

1. What are the primary approved indications for paroxetine? Paroxetine is approved for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder.

2. What is the current stage of clinical development for new paroxetine formulations? Current clinical development for new paroxetine formulations is primarily in Phase II and Phase III trials, focusing on pharmacokinetics, safety, and efficacy of improved delivery systems.

3. How does generic competition impact the pricing of paroxetine? Extensive generic competition has led to significant price erosion, with generic paroxetine tablets available at substantially lower costs than when it was a branded product.

4. What are the main therapeutic areas being explored in current paroxetine clinical trials? Current clinical trials are exploring new formulations, specific patient populations (e.g., adolescents, elderly), and adjunctive therapy for complex or treatment-resistant conditions.

5. What is the projected market trend for paroxetine over the next five years? The market for paroxetine is projected to experience modest, single-digit percentage growth in revenue, largely driven by sustained demand and its affordability as a generic medication.

Citations

[1] Grand View Research. (2023). Antidepressants Market Size, Share & Trends Analysis Report By Drug Class (SSRIs, SNRIs, Tricyclics, Others), By Indication (Depression, Anxiety, OCD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023-2030. [2] GoodRx. (2023). Paroxetine Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/paroxetine